Table 1 Characteristics of the 63 patients who received ddI/d4T (Group 1) versus ZDV/3TC (Group 2) as first-line therapy
| Â | Group 1 (n = 26) | Group 2 (n = 37) |
|---|---|---|
Age (years) Median Interquartile range | 35 [24-57] | 34 [21-48] |
Female sex (%) | 61.5 | 60.7 |
Baseline nadir CD4 cell count Median Interquartile range | 96 [2-276] | 61 [1-317] |
CD4 cell count at failure visit Median Interquartile range | 334 [41-937] | 233 [9-1313] |
Log10 HIV-1 RNA at failure visit Median Interquartile range | 4.2 [2.9-5.33] | 4.7 [3.5-5.9] |
Total days on antiretroviral therapy at the time of genotype Median Interquartile range | 998 [228-2507] | 486 [59-1346] |
Total time (days) to non-detectability of viral load (<400 copies/ml) at the time of genotype Median Interquartile range | 158 [28-1693] | 96 [10-1188] |
Average number of ARV regimens received by the time of genotype | 3* | 2.5†|